Pharmacokinetics of oral rufinamide in dogs
Version of Record online: 2 DEC 2011
© 2011 Blackwell Publishing Ltd
Journal of Veterinary Pharmacology and Therapeutics
Volume 35, Issue 6, pages 529–533, December 2012
How to Cite
WRIGHT, H. M., CHEN, A. V., MARTINEZ, S. E. and DAVIES, N. M. (2012), Pharmacokinetics of oral rufinamide in dogs. Journal of Veterinary Pharmacology and Therapeutics, 35: 529–533. doi: 10.1111/j.1365-2885.2011.01353.x
- Issue online: 7 NOV 2012
- Version of Record online: 2 DEC 2011
- (Paper received 26 July 2011; accepted for publication 3 November 2011)
Wright, H. M., Chen, A. V., Martinez, S. E., Davies, N. M. Pharmacokinetics of oral rufinamide in dogs. J. vet. Pharmacol. Therap. 35, 529–533.
The objective of this study was to determine the pharmacokinetic properties and short-term adverse effect profile of single-dose oral rufinamide in healthy dogs. Six healthy adult dogs were included in the study. The pharmacokinetics of rufinamide were calculated following administration of a single mean oral dose of 20.0 mg/kg (range 18.6–20.8 mg/kg). Plasma rufinamide concentrations were determined using high-performance liquid chromatography, and pharmacokinetic data were analyzed using commercial software. No adverse effects were observed. The mean terminal half-life was 9.86 ± 4.77 h. The mean maximum plasma concentration was 19.6 ± 5.8 μg/mL, and the mean time to maximum plasma concentration was 9.33 ± 4.68 h. Mean clearance was 1.45 ± 0.70 L/h. The area under the curve (to infinity) was 411 ± 176 μg·h/mL. Results of this study suggest that rufinamide given orally at 20 mg/kg every 12 h in healthy dogs should result in a plasma concentration and half-life sufficient to achieve the therapeutic level extrapolated from humans without short-term adverse effects. Further investigation into the efficacy and long-term safety of rufinamide in the treatment of canine epilepsy is warranted.